NEI Research News

Scientists at St. Jude Children’s Research Hospital identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer.

Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA).

Understanding the key structural determinants of a highly specialized membrane in the eye could lead to new treatments.

Using a stem-cell-derived model, researchers have identified two drug candidates that may slow dry age-related macular degeneration (AMD), a leading cause of blindness for which no treatment exists.

Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease.

CellSight researchers at the University of Colorado School of Medicine are offering the first evidence connecting drusen formation, or yellowish deposits that accumulate under the retina, with extracellular vesicles and age-related macular degeneration.

Researchers have uncovered the mechanism of vision loss in Usher syndrome, yielding additional drug targets for eventual development of better therapies.

The Medical College of Georgia scientists have early evidence that HBI-002, a low-dose oral compound, can safely reduce oxidative stress and inflammation in the retina, both early, major contributors to diabetic retinopathy.

As scientists move closer to testing regenerative therapies for eye disease, techniques are needed to monitor transplanted cells as they integrate with host tissues.

In a pair of papers on retinal structure, Duke University neurobiologists have shown that the rigors of natural selection and evolution have shaped the retinas in our eyes just as this theory of optimization would predict.